Search
Lepunafusp alfa
go.drugbank.com/drugs/DB19011InvestigationalLepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).
AMP-201
go.drugbank.com/drugs/DB18663ExperimentalAMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Minzasolmin
go.drugbank.com/drugs/DB18961InvestigationalMinzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
go.drugbank.com/drugs/DB02842Experimental9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
AAV8-RK-RetGC
go.drugbank.com/drugs/DB32389ExperimentalAAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.
Ciluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
Nemiralisib
go.drugbank.com/drugs/DB16253InvestigationalNemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary
Corticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalIt is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.